Charles River is pleased to participate in the scientific program of Drug Discovery Digital 2020. The largest in-person meeting of life science professionals in the UK is set to become the largest virtual drug discovery event hosted in the UK, treating online attendees to the latest ground-breaking research. Join us to discuss advances in the application of laboratory technology that are helping us understand disease biology and identify novel chemical and biological candidate drugs.
Mark your calendar and be sure to tune in for the presentations of our scientists, conference chair, Ian Waddell, PhD and Antti Nurmi, PhD.
Combining target class expertise with decades of cell biology and chemistry R&D, Charles River’s team of scientists can support your integrated development programs with accelerated hit discovery and lead optimization through sophisticated screening and profiling assay development and discovery chemistry services.
Want to set aside time to chat with our scientists? Email us at [email protected] to request a virtual consultation.
Don't miss our scientists at the following presentations:
Wednesday, October 7th, 2020, 11:40 AM | Innovations in Chemistry to Discover New Medicines
Use of the Developability Classicisation System to Guide Early Stage Development Projects | Darren Matthews, BSc PhD, Research Leader
Less than 5% of potential candidates make it through preclinical studies to a positive Phase III outcome. A significant contributor to this high attrition rate is a lack of efficacy as a result of poor bioavailability. In the past decade ‘simple’ tools, such as the Developability Classification System (DCS), have been proposed to reduce this attrition rate. In recent years the DCS has been successful at aiding formulation scientists developing formulation strategies for clinical studies. Utilization of the DCS earlier in development programme (i.e. Hit to lead and Lead Optimization) has aided and understanding of potential bioavailability challenges, guide development strategies and aid candidate nomination. An example of how the DCS was used to highlight potential challenges with a nominated compound and enabled a suitable strategy to be undertaken to ensure successful preclinical studies is presented.
Thursday, October 15th, 2020, 11:05 AM | Cancer Research UK
In Vitro Cell Based Cytotoxicity and T Cell Activation Assays to Assess Safety and Efficacy of Engineered T Cell Therapies | Sanne Holt, PhD, Group Leader Biology
CAR and T cell receptor engineered T cells are showing great promise in cancer clinical trials but a challenge remains with on-target tumor and off-target toxicities. We have developed in vitro assays utilizing primary human cells from healthy tissue and/or differentiated iPCS-derived cells to assess on-target off-tumor and/or off-target cytotoxicity for engineered T cell therapies. The developed safety assays provide a robust and rapid platform to assess cytotoxicity effects within immuno-oncology therapies, either TCR or CAR-T cells, in both early stage development or late stage testing of the therapeutic product.
Poster Presentations
|
Tuesday, October 6, 2020 | Better Hits-Better Therapeutics? |
|
Tuesday, October 13, 2020 | Patient relevant models for drug discovery |
|
Tuesday, October 13, 2020 | Patient relevant models for drug discovery |
|
Thursday, October 15, 2020 | Cancer Research UK |
Ian Waddell, PhD Executive Director of Biology, will introduce the conference keynote speakers on Tuesday, October 6 and Wednesday, October 14.
Antti Nurmi, Director, will introduce the speakers during the Patient Relevant Models for Drug Discovery track on Tuesday, October 13.
Marjin Vlaming, Head of Biology, will be a panelist at the hot topic session organized by Bit.Bio on Tuesday, October 13.